BIOVECTRA, a part of Agilent Technologies Inc., and Revolution Biomanufacturing Inc. today announced a collaboration that grants BIOVECTRA access to Revolution Biomanufacturing's proprietary platforms ...
The clinical potential of mRNA was revealed with COVID-19 vaccines, but that was just the beginning. “Today, this Nobel prize–winning technology is being leveraged for many therapeutic applications, ...
Peking University, June 27, 2025: To overcome the inherent challenge of translation termination interference caused by stop codon reprogramming in mammalian cells, researchers from Peking University ...
Vaccines have been reliably and affordably protecting people from diseases worldwide for centuries. Until the COVID-19 pandemic, however, vaccine development was still a long and idiosyncratic process ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback